Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of the Intrathecal Injection of Active Allogeneic Natural Killer Cells in Patients With High-grade Gliomas; A Multi-center Phase II Clinical Trial

NCT06687681 is registered in ClinicalTrials.gov with Marzieh Ebrahimi as lead sponsor.

NCT NCT06687681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06687681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of the Intrathecal Injection of Active Allogeneic Natural Killer Cells in Patients With High-grade Gliomas; A Multi-center Phase II Clinical Trial
Lead sponsor
Marzieh Ebrahimi
Phase
Phase 2
Overall status
Recruiting
Start date
November 25, 2024
Completion date
November 25, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma glioblastoma multiforme, high grade glioma (iii or iv)